Skip to content
Tablet Allopathic

Cavazide 75 mg+12.5 mg tablet

Generic: Irbesartan + Hydrochlorothiazide

Company: UniMed UniHealth Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength75 mg+12.5 mg
PackStrip: 60.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated January 15, 2026.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Irbesartan + Hydrochlorothiazide 75 mg+12.5 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Cavazide (this medicine)6.00 taka per tablet
Arbitan Plus, box of 306.03 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Irbesartan + Hydrochlorothiazide guide

Indications

Hypertension Irbesartan & Hydrochlorothiazide tablet are indicated for the treatment of hypertension. This tablet may be used in patients whose blood pressure is not adequately controlled on monotherapy. This tablet may also be used as initial therapy in patients who are likely to need multiple drugs to achieve ... Read more Irbesartan & Hydrochlorothiazide tablet are indicated for the treatment of hypertension. This tablet may be used in patients whose blood pressure is not adequately controlled on monotherapy. This tablet may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Irbesartan & Hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy.

Dosage and administration

Initial therapy: Irbesartan 150 mg & Hydrochlorothiazide 12.5 mg orally once a day; may increase after 1 to 2 weeks. Add-on/Replacement therapy: Irbesartan 150 to 300 mg & Hydrochlorothiazide 12.5 to 25 mg orally once a day Maximum dose: Irbesartan 300 mg & Hydrochlorothiazide 25 mg orally once a day

Side effects

Irbesartan: Hyperkalemia (19%), Chest pain (2%), Tachycardia (1%), Abnormal urination (2%), Musculoskeletal pain (6%), Flu-like syndrome (3%), Edema (3%), Tachycardia (1%), Chest pain (2%), Creatinine increased (1%), Increased BUN (2%), Dizziness (10%), URI (9%), Orthostatic hypotension (5%), Fatigue (4%), Diarrhea (3%), Dyspepsia (2%) Hydrochlorothiazide: Anorexia, Epigastric distress, Hypotension, Orthostatic hypotension, Photosensitivity, Anaphylaxis, Anemia, Confusion, Erythema multiforme, Stevens-Johnson syndrome, Exfoliative dermatitis including toxic epidermal necrolysis, Dizziness, Hypokalemia and/or hypomagnesemia, Hyperuricemia, Headache

Precautions and warnings

Child: Do not nurse Lactation: Discontinue drug or do not nurse

Pregnancy and lactation

Pregnancy Category D. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Irbesartan and Hydrochlorothiazide as soon as possible. Thiazides cross the placenta, and use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults. Nursing Mothers: It is not known whether irbesartan is excreted in human milk, but irbesartan or some metabolite of irbesartan is secreted at low concentration in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250